Compare GIII & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIII | COLL |
|---|---|---|
| Founded | 1956 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1989 | 2015 |
| Metric | GIII | COLL |
|---|---|---|
| Price | $29.82 | $45.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $31.20 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 506.8K | 481.4K |
| Earning Date | 12-09-2025 | 02-26-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.27 | 1.63 |
| Revenue | ★ $3,025,059,000.00 | $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ $9.26 | $30.01 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $20.33 | $23.23 |
| 52 Week High | $34.83 | $50.79 |
| Indicator | GIII | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 42.40 |
| Support Level | $29.17 | $44.51 |
| Resistance Level | $30.71 | $49.17 |
| Average True Range (ATR) | 0.92 | 1.66 |
| MACD | -0.14 | -0.48 |
| Stochastic Oscillator | 40.53 | 10.04 |
G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenues from Wholesale operations.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.